$50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Legislation related to spinal cord injury research and treatment. Legislation related to central nervous system research and therapeutics. Legislation related to spinal cord injury research, therapeutics and approvals."
You can find more data on corporate lobbying on Quiver Quantitative.
NGEN Hedge Fund Activity
We have seen 39 institutional investors add shares of NGEN stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PFG INVESTMENTS, LLC added 201,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $757,770
- BANK OF AMERICA CORP /DE/ added 200,656 shares (+inf%) to their portfolio in Q1 2026, for an estimated $756,473
- MARSHALL WACE, LLP added 200,359 shares (+inf%) to their portfolio in Q1 2026, for an estimated $755,353
- ROYAL BANK OF CANADA added 171,961 shares (+inf%) to their portfolio in Q1 2026, for an estimated $648,292
- INTEGRATED WEALTH CONCEPTS LLC added 86,815 shares (+inf%) to their portfolio in Q1 2026, for an estimated $327,292
- VALLEY FORGE INVESTMENT CONSULTANTS INC ADV added 77,698 shares (+inf%) to their portfolio in Q1 2026, for an estimated $292,921
- BANK OF MONTREAL /CAN/ added 62,900 shares (+inf%) to their portfolio in Q1 2026, for an estimated $237,133
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
